Dyslipidemia - Pipeline Review - 2019
Firstview Insight's Dyslipidemia - Pipeline Review-2019 provides an overview of the pipeline landscape of Dyslipidemia It provides comprehensive insights of all the clinical and non-clinical therapeutics in development with detailed description about the collaborations; deals; designations; patent information etc.These reports encourage the clients in distinguishing the upcoming and existing competitors in their separate therapeutic spaces. The report provides detailed description of the competitor profiles with key milestones and evidence along with analysis by mechanism of action; route of administration; molecule type; stage of development. Information obtained from multiple sources will be used to triangulate and update the profiles. The report also provides key events in the last year related to the indication. This report provides detailed analysis of all the products along with the companies involved.
Dyslipidemia is an abnormal amount of lipids (e.g. triglycerides, cholesterol and/or fat phospholipids) in the blood. In developed countries, most dyslipidemias are hyperlipidemias; that is, an elevation of lipids in the blood. This is often due to diet and lifestyle. Prolonged elevation of insulin levels can also lead to dyslipidemia. Likewise, increased levels of O-GlcNAc transferase (OGT) may cause dyslipidemi.tthe most common forms of dyslipidemia involve:
high levels of low-density lipoproteins (LDL), or bad cholesterol
low levels of high-density lipoproteins (HDL), or good cholesterol
high levels of triglycerides
high cholesterol, which refers to high LDL and triglyceride levels
Lipids, or fats, are building blocks of life and provide energy to cells. Lipids include:
LDL cholesterol, which is considered bad because it can cause plaques to form in the blood vessels.
HDL cholesterol, which is regarded as good because it can help to remove LDL from the blood.
Triglycerides, which develop when calories are not burned right away and are stored in fat cells.
Drug Profile Overview:
The pipeline section provides descriptive drug profiles for the pipeline products including product description, mechanism of action, route of administration, molecule type, technology involved, chemical information.
Clinical Trial Overview:
This section of the report focuses on the clinical activity of the molecule. It includes both clinical and pre-clinical activity which provides detailed information about the safety, efficacy, tolerability, toxicity of pipeline drugs. A graphical representation of the clinical trial landscape of pipeline therapy which includes information about phase of development, trial design, treatment arms, dosage and frequency, formulation of the drug, primary and secondary completion date, enrolment number, exclusion and inclusion criteria, line of therapy. This section also includes the clinical trial results and analysis based on those results.
Product Development Activity:
This section of the report focuses on detail information about designations, exclusivity details, technology, licensing and collaboration, funding and financing, key milestones and various other development activities.
Company Overview:
Company profile includes the detail about type of company, headquarter, global presence, research focus and key financial
Scope
Dyslipidemia is an abnormal amount of lipids (e.g. triglycerides, cholesterol and/or fat phospholipids) in the blood. In developed countries, most dyslipidemias are hyperlipidemias; that is, an elevation of lipids in the blood. This is often due to diet and lifestyle. Prolonged elevation of insulin levels can also lead to dyslipidemia. Likewise, increased levels of O-GlcNAc transferase (OGT) may cause dyslipidemi.tthe most common forms of dyslipidemia involve:
high levels of low-density lipoproteins (LDL), or bad cholesterol
low levels of high-density lipoproteins (HDL), or good cholesterol
high levels of triglycerides
high cholesterol, which refers to high LDL and triglyceride levels
Lipids, or fats, are building blocks of life and provide energy to cells. Lipids include:
LDL cholesterol, which is considered bad because it can cause plaques to form in the blood vessels.
HDL cholesterol, which is regarded as good because it can help to remove LDL from the blood.
Triglycerides, which develop when calories are not burned right away and are stored in fat cells.
Drug Profile Overview:
The pipeline section provides descriptive drug profiles for the pipeline products including product description, mechanism of action, route of administration, molecule type, technology involved, chemical information.
Clinical Trial Overview:
This section of the report focuses on the clinical activity of the molecule. It includes both clinical and pre-clinical activity which provides detailed information about the safety, efficacy, tolerability, toxicity of pipeline drugs. A graphical representation of the clinical trial landscape of pipeline therapy which includes information about phase of development, trial design, treatment arms, dosage and frequency, formulation of the drug, primary and secondary completion date, enrolment number, exclusion and inclusion criteria, line of therapy. This section also includes the clinical trial results and analysis based on those results.
Product Development Activity:
This section of the report focuses on detail information about designations, exclusivity details, technology, licensing and collaboration, funding and financing, key milestones and various other development activities.
Company Overview:
Company profile includes the detail about type of company, headquarter, global presence, research focus and key financial
Scope
- The report provides a competitive landscape
- The report also provides clinical trial landscape of the pipeline drugs including status; trial phase; sponsor type and end-point status
- The report provides the list of companies which are the most active in the pipeline
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery
- The report provides descriptive drug profiles which includes product description; comprising detailed mechanism of action (MoA); route of administration (RoA); Stage of development; clinical trial status; licensing and collaboration details & other developmental activities
- The report features comparative analysis of product profiles based on molecule type; mechanism of action (MoA); route of administration (RoA)
- The report summarizes all the dormant and discontinued pipeline projects
- The report also provides latest news for the past one year
- To identifying prominent players in the treatment landscape
- To determine the drivers; barriers and unmet need in the treatment space
- Gain strategically significant competitor information; analysis; and insights to formulate effective R&D strategies
- Define in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- To understand the composition of the pipeline in terms of molecule type; molecular target; mechanism of action and route of administration
1. DISEASE OVERVIEW
1.1. Pathophysiology
1.2. Symptoms
1.3. Etiology
1.4. Diagnosis
1.5. Etiology
1.6. Treatment Algorithm
1.7. Treatment Options
2. FEATURED NEWS AND PRESS RELEASES, 2018-2066
3. LIST OF COMPANIES DEVELOPING PRODUCTS FOR DYSLIPIDEMIA
4. TREATMENT ALGORITHM
5. CURRENT UNMET NEEDS
6. MARKET TRENDS
7. PIPELINE THERAPEUTICS
8. THERAPEUTICS UNDER DEVELOPMENT BY COMPANIES
9. LATE STAGE PRODUCTS (PHASE III)
9.1 Drug 1
9.1.1. Product Description
9.1.2. Research and Development
9.1.3. Product Development Activities
9.2. Drug 2
9.2.1. Product Description
9.2.2. Research and Development
9.2.3. Product Development Activities
10. MID STAGE PRODUCTS (PHASE II)
10.1 Drug 1
10.1.1. Product Description
10.1.2. Research and Development
10.1.3. Product Development Activities
10.2. Drug 2
10.2.1. Product Description
10.2.2. Research and Development
10.2.3. Product Development Activities
11. EARLY STAGE AND PRECLINICAL PRODUCTS (PHASE II)
11.1 Drug 1
11.1.1. Product Description
11.1.2. Research and Development
11.1.3. Product Development Activities
11.2. Drug 2
11.2.1. Product Description
11.2.2. Research and Development
11.2.3. Product Development Activities
12. DRIVERS OF DYSLIPIDEMIA
13. CONSTRAINTS OF DYSLIPIDEMIA
14. THERAPEUTIC ASSESSMENT
14.1. Assessment by Route of Administration
14.2. Assessment by Phase & Route of Administration
14.3. Assessment by Molecule Type
14.4. Assessment by Phase & Molecule type
14.5. Assessment by Target
14.6. Assessment by Mechanism of Action
15. COLLABORATIONS AND ACQUISITIONS DETAILS
16. DORMANT PRODUCTS
17. DISCONTINUED PRODUCTS
18. MARKET TRENDS
19. MARKET OPPORTUNITY ASSESSMENT
20. UNMET NEEDS
21. SWOT ANALYSIS
22. APPENDIX
23. REPORT METHODOLOGY
24. CONSULTING SERVICES
25. DISCLAIMER
1.1. Pathophysiology
1.2. Symptoms
1.3. Etiology
1.4. Diagnosis
1.5. Etiology
1.6. Treatment Algorithm
1.7. Treatment Options
2. FEATURED NEWS AND PRESS RELEASES, 2018-2066
3. LIST OF COMPANIES DEVELOPING PRODUCTS FOR DYSLIPIDEMIA
4. TREATMENT ALGORITHM
5. CURRENT UNMET NEEDS
6. MARKET TRENDS
7. PIPELINE THERAPEUTICS
8. THERAPEUTICS UNDER DEVELOPMENT BY COMPANIES
9. LATE STAGE PRODUCTS (PHASE III)
9.1 Drug 1
9.1.1. Product Description
9.1.2. Research and Development
9.1.3. Product Development Activities
9.2. Drug 2
9.2.1. Product Description
9.2.2. Research and Development
9.2.3. Product Development Activities
10. MID STAGE PRODUCTS (PHASE II)
10.1 Drug 1
10.1.1. Product Description
10.1.2. Research and Development
10.1.3. Product Development Activities
10.2. Drug 2
10.2.1. Product Description
10.2.2. Research and Development
10.2.3. Product Development Activities
11. EARLY STAGE AND PRECLINICAL PRODUCTS (PHASE II)
11.1 Drug 1
11.1.1. Product Description
11.1.2. Research and Development
11.1.3. Product Development Activities
11.2. Drug 2
11.2.1. Product Description
11.2.2. Research and Development
11.2.3. Product Development Activities
12. DRIVERS OF DYSLIPIDEMIA
13. CONSTRAINTS OF DYSLIPIDEMIA
14. THERAPEUTIC ASSESSMENT
14.1. Assessment by Route of Administration
14.2. Assessment by Phase & Route of Administration
14.3. Assessment by Molecule Type
14.4. Assessment by Phase & Molecule type
14.5. Assessment by Target
14.6. Assessment by Mechanism of Action
15. COLLABORATIONS AND ACQUISITIONS DETAILS
16. DORMANT PRODUCTS
17. DISCONTINUED PRODUCTS
18. MARKET TRENDS
19. MARKET OPPORTUNITY ASSESSMENT
20. UNMET NEEDS
21. SWOT ANALYSIS
22. APPENDIX
23. REPORT METHODOLOGY
24. CONSULTING SERVICES
25. DISCLAIMER
LIST OF TABLES
Table 1: Marketed Dyslipidemia drugs, 2019
Table 2: Sales of Marketed drugs
Table 3: Patent expiration details – marketed drugs
Table 4: Number of Products Under Development for Dyslipidemia
Table 5: Products under Development by Companies
Table 6: Late Stage Products
Table 7: Mid Stage Products
Table 8: Early Stage Products
Table 9: Pre-Clinical and Discovery Products
Table 10: Assessment by Route of Administration
Table 11: Assessment by Stage and Route of Administration
Table 12: Assessment by Molecule Type
Table 13: Assessment by Stage and Molecule Type
Table 14: Assessment by Target
Table 15: Assessment by Mechanism of Action
Table 16: Dormant Products
Table 17: Discontinued Products
Table 1: Marketed Dyslipidemia drugs, 2019
Table 2: Sales of Marketed drugs
Table 3: Patent expiration details – marketed drugs
Table 4: Number of Products Under Development for Dyslipidemia
Table 5: Products under Development by Companies
Table 6: Late Stage Products
Table 7: Mid Stage Products
Table 8: Early Stage Products
Table 9: Pre-Clinical and Discovery Products
Table 10: Assessment by Route of Administration
Table 11: Assessment by Stage and Route of Administration
Table 12: Assessment by Molecule Type
Table 13: Assessment by Stage and Molecule Type
Table 14: Assessment by Target
Table 15: Assessment by Mechanism of Action
Table 16: Dormant Products
Table 17: Discontinued Products
LIST OF FIGURES
Figure 1: Marketed and PipelineDyslipidemia drugs, 2019
Figure 2: Sales of Marketed drugs
Figure 3: Patent expiration details – marketed drugs
Figure 4: Number of Products Under Development for Dyslipidemia
Figure 5: Products under Development by Companies
Figure 6: Late Stage Products
Figure 7: Mid Stage Products
Figure 8: Early Stage Products
Figure 9: Pre-Clinical and Discovery Products
Figure 10: Assessment by Route of Administration
Figure 11: Assessment by Stage and Route of Administration
Figure 12: Assessment by Molecule Type
Figure 13: Assessment by Stage and Molecule Type
Figure 14: Assessment by Target
Figure 15: Assessment by Mechanism of Action
Figure 16: Dormant Products
Figure17: Discontinued Products
Figure 1: Marketed and PipelineDyslipidemia drugs, 2019
Figure 2: Sales of Marketed drugs
Figure 3: Patent expiration details – marketed drugs
Figure 4: Number of Products Under Development for Dyslipidemia
Figure 5: Products under Development by Companies
Figure 6: Late Stage Products
Figure 7: Mid Stage Products
Figure 8: Early Stage Products
Figure 9: Pre-Clinical and Discovery Products
Figure 10: Assessment by Route of Administration
Figure 11: Assessment by Stage and Route of Administration
Figure 12: Assessment by Molecule Type
Figure 13: Assessment by Stage and Molecule Type
Figure 14: Assessment by Target
Figure 15: Assessment by Mechanism of Action
Figure 16: Dormant Products
Figure17: Discontinued Products
